

FORM 62-103F1

REQUIRED DISCLOSURE UNDER THE EARLY WARNING REQUIREMENTS

State if the report is filed to amend information disclosed in an earlier report. Indicate the date of the report that is being amended.

This report amends the report by Shenzhen Hepalink Pharmaceutical Co, Ltd. dated July 24, 2015.

Item 1. Security and Reporting Issuer

1.1 State the designation of securities to which this report relates and the name and address of the head office of the issuer of the securities.

Units, each being comprised of one common share (“Share”) and 0.082759 of one common share purchase warrant (“Warrant”) of:

Resverlogix Corp. (the “Issuer”)
300, 4820 Richard Road SW
Calgary, Alberta T3E 6L1

1.2 State the name of the market in which the transaction or other occurrence that triggered the requirement to file this report took place.

Not applicable

Item 2. Identity of the Acquiror

2.1 State the name and address of the acquiror.

Shenzhen Hepalink Pharmaceutical Co., Ltd. (“Hepalink”)
21 Langshan Road, Song Ping Shan
NanShan District, Shenzhen, 518057
People’s Republic of China

2.2 State the date of the transaction or other occurrence that triggered the requirement to file this report and briefly describe the transaction or other occurrence.

On December 1, 2017, Hepalink acquired 60,416,667 units of the Issuer (“Units”) by way of a private placement (the “Private Placement”) at a price of Cdn\$1.44 per Unit, for an aggregate purchase price of Cdn\$87 million. Each Unit is comprised of one Share and 0.082759 of one Warrant. Each whole Warrant entitles the holder to purchase one Share at an exercise price of Cdn\$1.64 for a term of four years.

2.3 State the names of any joint actors.

Not applicable

Item 3. Interest in Securities of the Reporting Issuer

3.1 State the designation and number or principal amount of securities acquired or disposed of that triggered the requirement to file the report and the change in the acquiror's securityholding percentage in the class of securities.

Hepalink acquired 60,416,667 Shares and 5,000,023 Warrants. The acquisition resulted in the Hepalink's securityholding percentage of Shares increasing from 12.74% to 42.86%.

3.2 State whether the acquiror acquired or disposed ownership of, or acquired or ceased to have control over, the securities that triggered the requirement to file the report.

Hepalink acquired beneficial ownership of and control over 60,416,667 Shares and 5,000,023 Warrants, which triggered the requirement to file this report.

3.3 If the transaction involved a securities lending arrangement, state that fact.

Not Applicable.

3.4 State the designation and number or principal amount of securities and the acquiror's securityholding percentage in the class of securities, immediately before and after the transaction or other occurrence that triggered the requirement to file this report.

Prior to completion of the Private Placement, Hepalink held 14,603,333 common shares and 2,333,333 common share purchase warrants of the Issuer which represented 12.74% of common shares outstanding before giving effect to any outstanding warrants and 14.48% of the outstanding common shares assuming the exercise by Hepalink of its warrants.

After giving effect to the Private Placement, Hepalink held 75,020,000 common shares and 7,333,333 common share purchase warrants which represents 42.86% of the common shares outstanding before giving effect to any outstanding warrants and 45.16% of the outstanding common shares assuming the exercise by Hepalink of its warrants.

3.5 State the designation and number or principal amount of securities and the acquiror's securityholding percentage in the class of securities referred to in Item 3.4 over which

(a) the acquiror, either alone or together with any joint actors, has ownership and control,

Hepalink owns, directly or indirectly, all of the securities described above.

(b) the acquiror, either alone or together with any joint actors, has ownership but control is held by persons or companies other than the acquiror or any joint actor, and

Not Applicable.

(c) the acquiror, either alone or together with any joint actors, has exclusive or shared control but does not have ownership.

Not Applicable.

- 3.6** If the acquiror or any of its joint actors has an interest in, or right or obligation associated with, a related financial instrument involving a security of the class of securities in respect of which disclosure is required under this item, describe the material terms of the related financial instrument and its impact on the acquiror's securityholdings.

Not Applicable.

- 3.7** If the acquiror or any of its joint actors is a party to a securities lending arrangement involving a security of the class of securities in respect of which disclosure is required under this item, describe the material terms of the arrangement including the duration of the arrangement, the number or principal amount of securities involved and any right to recall the securities or identical securities that have been transferred or lent under the arrangement.

Not Applicable.

State if the securities lending arrangement is subject to the exception provided in section 5.7 of NI 62-104.

Not Applicable.

- 3.8** If the acquiror or any of its joint actors is a party to an agreement, arrangement or understanding that has the effect of altering, directly or indirectly, the acquiror's economic exposure to the security of the class of securities to which this report relates, describe the material terms of the agreement, arrangement or understanding.

Not Applicable.

Item 4. Consideration Paid

- 4.1** State the value, in Canadian dollars, of any consideration paid or received per security and in total.

The Units were purchased at \$1.44 per Unit and the total consideration paid by Hepalink for the Units was Cdn\$87 million.

- 4.2** In the case of a transaction or other occurrence that did not take place on a stock exchange or other market that represents a published market for the securities, including an issuance from treasury, disclose the nature and value, in Canadian dollars, of the consideration paid or received by the acquiror.

See item 4.1 above.

- 4.3** If the securities were acquired or disposed of other than by purchase or sale, describe the method of acquisition or disposition.

Not Applicable.

Item 5. Purpose of the Transaction

State the purpose or purposes of the acquiror and any joint actors for the acquisition or disposition of securities of the reporting issuer.

The Units were acquired for investment purposes.

Describe any plans or future intentions which the acquiror and any joint actors may have which relate to or would result in any of the following:

- (a) **the acquisition of additional securities of the reporting issuer, or the disposition of securities of the reporting issuer;**

Hepalink or any of its joint actors may, in the future and subject to applicable law, acquire or dispose of Shares or other securities of the Issuer depending upon a number of factors, including but not limited to general market and economic conditions and other available investment opportunities.

- (b) **a corporate transaction, such as a merger, reorganization or liquidation, involving the reporting issuer or any of its subsidiaries;**

Not Applicable.

- (c) **a sale or transfer of a material amount of the assets of the reporting issuer or any of its subsidiaries;**

Not Applicable.

- (d) **a change in the board of directors or management of the reporting issuer, including any plans or intentions to change the number or term of directors or to fill any existing vacancy on the board;**

Not Applicable.

- (e) **a material change in the present capitalization or dividend policy of the reporting issuer;**

Not Applicable.

- (f) **a material change in the reporting issuer's business or corporate structure;**

Not Applicable.

- (g) **a change in the reporting issuer's charter, bylaws or similar instruments or another action which might impede the acquisition of control of the reporting issuer by any person or company;**

Not Applicable.

- (h) **a class of securities of the reporting issuer being delisted from, or ceasing to be authorized to be quoted on, a marketplace;**

Not Applicable.

- (i) **the issuer ceasing to be a reporting issuer in any jurisdiction of Canada;**

Not Applicable.

- (j) **a solicitation of proxies from securityholders;**

Not Applicable.

- (k) **an action similar to any of those enumerated above.**

Not Applicable.

Item 6. Agreements, Arrangements, Commitments or Understandings With Respect to Securities of the Reporting Issuer

Describe the material terms of any agreements, arrangements, commitments or understandings between the acquiror and a joint actor and among those persons and any person with respect to securities of the class of securities to which this report relates, including but not limited to the transfer or the voting of any of the securities, finder's fees, joint ventures, loan or option arrangements, guarantees of profits, division of profits or loss, or the giving or withholding of proxies. Include such information for any of the securities that are pledged or otherwise subject to a contingency, the occurrence of which would give another person voting power or investment power over such securities, except that disclosure of standard default and similar provisions contained in loan agreements need not be included.

Hepalink and the Issuer entered into a Share Restriction Agreement dated July 20, 2015 whereby Hepalink agreed not to sell the 13,270,000 common shares and 1,000,000 warrants acquired pursuant to a private placement on July 20, 2015 for a period of three years and after such period to offer such securities for sale to the Issuer prior to any resale to a third party.

Item 7. Change in material fact

If applicable, describe any change in a material fact set out in a previous report filed by the acquiror under the early warning requirements or Part 4 in respect of the reporting issuer's securities.

Not Applicable.

Item 8. Exemption

If the acquiror relies on an exemption from requirements in securities legislation applicable to formal bids for the transaction, state the exemption being relied on and describe the facts supporting that reliance.

Not Applicable.

Item 9. Certification

The acquiror must certify that the information is true and complete in every respect. In the case of an agent, the certification is based on the agent's best knowledge, information and belief but the acquiror is still responsible for ensuring that the information filed by the agent is true and complete.

This report must be signed by each person on whose behalf the report is filed or his authorized representative.

It is an offence to submit information that, in a material respect and at the time and in the light of the circumstances in which it is submitted, is misleading or untrue.

Certificate

I, as the acquiror, certify, or I, as the agent filing the report on behalf of an acquiror, certify to the best of my knowledge, information and belief, that the statements made in this report are true and complete in every respect.

December 5, 2017

Date

(signed) "Li Li"

Signature

Li Li/Chairman

Name/Title